Filters
New
Hikma – A legacy of quality for a better future
Insight, Corporate 24 June 2024
New
Hikma acquires Xellia’s differentiated portfolio and enhances Injectables pipeline, manufacturing capabilities and R&D
Press Release, Corporate 17 June 2024
Hikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House mee...
Press Release, Corporate 06 June 2024
Hikma opens new UK office to support NHS supply, strengthening European presence
Press Release, Corporate 03 June 2024
Hikma enters the Spanish generic injectables market, strengthening its European presence
Press Release, Corporate 20 May 2024
Hikma launches Midazolam Injection, USP, in a prefilled syringe in the US
Press Release, Corporate 08 May 2024
Bringing Better Health Within Reach: Hikma’s journey to become the Partner of choice in MENA
Insight, Corporate 29 April 2024
Hikma has strong start to 2024, with continued momentum across all businesses. Full year guidance reiterated
Press Release, Financial Results 25 April 2024
Hikma appoints Dr. Hafrun Fridriksdottir as President of Generics business
Press Release, Corporate 15 April 2024
Hikma’s Executive Vice Chairman and President of MENA Joins Rakuten Medical’s Board of Directors
Press Release, Corporate 07 March 2024
Hikma delivers strong 2023 performance and a positive outlook for 2024
Press Release, Financial Results 22 February 2024
Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility
Press Release, Corporate 21 February 2024
Hikma launches Fentanyl Citrate Injection, USP, in a prefilled syringe in the US
Press Release, Product 20 February 2024
Hikma launches Alvimopan Capsules in the US
Press Release, Product 13 February 2024
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic®...
Press Release, Business Development 12 February 2024
You have viewed 15 of 430 results